Chardan lowered the firm’s price target on Tenaya Therapeutics (TNYA) to $9 from $18 and keeps a Buy rating on the shares. The firm’s updated model incorporates equity dilution from the March ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

(RTTNews) - South San Francisco, California-based Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, has priced its underwritten public offering of 75 million units at $0.70 ...

Tenaya Therapeutics is a clinical-stage biotechnology ... while the worst include Trade Desk and West Pharmaceutical. We sell different types of products and services to both investment ...

March 10, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies ...

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) have been given a consensus rating of “Buy” by the six research firms that are covering the firm, Marketbeat.com reports.

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...